Korro Bio (NASDAQ:KRRO) Director Sells $55,269.90 in Stock

Posted by Geri Gentry on Jun 24th, 2026

Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) Director Jean Francois Formela sold 3,962 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $13.95, for a total transaction of $55,269.90. Following the sale, the director owned 194,075 shares of the company’s stock, valued at approximately $2,707,346.25. This represents a 2.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jean Francois Formela also recently made the following trade(s):

On Wednesday, June 24th, Jean Francois Formela sold 48,438 shares of Korro Bio stock. The stock was sold at an average price of $14.61, for a total value of $707,679.18.
On Tuesday, June 23rd, Jean Francois Formela sold 119,005 shares of Korro Bio stock. The shares were sold at an average price of $14.25, for a total value of $1,695,821.25.
On Thursday, May 28th, Jean Francois Formela sold 2,860 shares of Korro Bio stock. The shares were sold at an average price of $13.95, for a total value of $39,897.00.

Korro Bio Stock Performance

Shares of NASDAQ KRRO traded up $0.06 during midday trading on Wednesday, hitting $13.77. 448,896 shares of the company’s stock traded hands, compared to its average volume of 200,441. The firm has a fifty day moving average of $12.20 and a 200 day moving average of $11.14. Korro Bio, Inc. has a 1 year low of $5.20 and a 1 year high of $55.89. The stock has a market capitalization of $198.56 million, a price-to-earnings ratio of -1.18 and a beta of 3.00.

Korro Bio (NASDAQ:KRRO – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Korro Bio had a negative return on equity of 117.86% and a negative net margin of 1,834.48%. On average, equities analysts anticipate that Korro Bio, Inc. will post -5.36 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Affinity Asset Advisors LLC purchased a new stake in Korro Bio in the 1st quarter worth $8,002,000. Nantahala Capital Management LLC purchased a new position in shares of Korro Bio in the fourth quarter valued at about $4,806,000. ADAR1 Capital Management LLC purchased a new position in shares of Korro Bio in the first quarter valued at about $6,113,000. TCG Crossover Management LLC bought a new position in shares of Korro Bio in the third quarter worth about $19,937,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Korro Bio by 6,185.5% in the third quarter. JPMorgan Chase & Co. now owns 199,249 shares of the company’s stock worth $9,542,000 after acquiring an additional 196,079 shares during the period. Institutional investors own 13.18% of the company’s stock.

Analyst Upgrades and Downgrades

KRRO has been the subject of a number of recent research reports. JonesTrading raised shares of Korro Bio from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. Raymond James Financial raised Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 target price on the stock in a report on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Korro Bio in a research report on Wednesday, April 8th. Wall Street Zen raised Korro Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Lifesci Capital raised Korro Bio to a “strong-buy” rating in a research note on Friday, May 29th. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.71.

Get Our Latest Analysis on KRRO

Korro Bio Company Profile

(Get Free Report)

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.